ATE150308T1 - Hemmung von thrombin - Google Patents

Hemmung von thrombin

Info

Publication number: ATE150308T1
Authority: AT; Austria
Prior art keywords: chem; thrombin; inhibition; hexamethyleneamino; pyrrolidino
Prior art date: 1993-12-21

Application number

AT94309472T

Other languages

English (en)

Inventor

Daniel Jon Sall

Gerald Floyd Smith

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-12-21

Filing date

1994-12-19

Publication date

1997-04-15

1994-12-19 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1997-04-15 Application granted granted Critical

1997-04-15 Publication of ATE150308T1 publication Critical patent/ATE150308T1/de

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)

AT94309472T 1993-12-21 1994-12-19 Hemmung von thrombin ATE150308T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/171,394 US5441965A (en)	1993-12-21	1993-12-21	Methods of inhibiting thrombin

Publications (1)

Publication Number	Publication Date
ATE150308T1 true ATE150308T1 (de)	1997-04-15

Family

ID=22623580

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94309472T ATE150308T1 (de)	1993-12-21	1994-12-19	Hemmung von thrombin

Country Status (21)

Country	Link
US (3)	US5441965A (de)
EP (1)	EP0664126B1 (de)
JP (1)	JPH07223947A (de)
KR (1)	KR950016744A (de)
CN (1)	CN1078070C (de)
AT (1)	ATE150308T1 (de)
AU (1)	AU693822B2 (de)
CA (1)	CA2138493A1 (de)
CZ (1)	CZ287725B6 (de)
DE (1)	DE69402173T2 (de)
DK (1)	DK0664126T3 (de)
ES (1)	ES2102154T3 (de)
GR (1)	GR3023537T3 (de)
HU (1)	HU224915B1 (de)
IL (1)	IL112048A (de)
NO (1)	NO313081B1 (de)
NZ (1)	NZ270185A (de)
RU (1)	RU94045846A (de)
TW (1)	TW321601B (de)
UA (1)	UA29446C2 (de)
ZA (1)	ZA9410084B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6515009B1 (en)	1991-09-27	2003-02-04	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en)	1993-01-28	1998-09-22	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en)	1993-05-13	2001-06-26	Neorx Corporation	Prevention and treatment of cardiovascular pathologies
US6395494B1 (en)	1993-05-13	2002-05-28	Neorx Corporation	Method to determine TGF-β
US5770609A (en)	1993-01-28	1998-06-23	Neorx Corporation	Prevention and treatment of cardiovascular pathologies
US6491938B2 (en)	1993-05-13	2002-12-10	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en)	1993-01-28	1997-01-21	Neorx Corporation	Method for identifying an agent which increases TGF-beta levels
EP0710116B1 (de)	1993-05-13	2008-09-03	Poniard Pharmaceuticals, Inc.	Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US6562862B1 (en)	1994-10-20	2003-05-13	Eli Lilly And Company	Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5545641A (en) *	1994-10-20	1996-08-13	Eli Lilly And Company	Methods of inhibiting physiological conditions associated with an excess of bradykinin
US5484808A (en) *	1995-02-09	1996-01-16	Eli Lilly And Company	Methods of inhibiting cell-cell adhesion
US5840747A (en) *	1995-06-07	1998-11-24	Eli Lilly And Company	Calcium channel antagonists
US6545027B1 (en) *	1995-06-07	2003-04-08	Eli Lilly And Company	Methods of modulating NF-kB transcription factor
JPH11510479A (ja) *	1995-06-07	1999-09-14	ネオルックスコーポレイション	タモキシフェン類似体による心臓血管疾病の予防及び治療
ES2180702T3 (es) *	1995-06-07	2003-02-16	Lilly Co Eli	Tratamiento de patologias por la induccion del factor de transcripcion bef-1.
DE69634045T2 (de)	1995-10-31	2005-05-19	Eli Lilly And Co., Indianapolis	Antithrombotische diamine
TW442286B (en) *	1996-02-28	2001-06-23	Pfizer	New therapeutic uses of estrogen agonists
IL120266A (en)	1996-02-28	2005-05-17	Pfizer	Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5811437A (en) *	1996-05-21	1998-09-22	Eli Lilly And Company	Methods of increasing nitric oxide synthesis
US5747509A (en) *	1996-06-03	1998-05-05	Schering Aktiengesellschaft	Method for lowering plasma levels of lipoprotein(a)
ZA982877B (en) *	1997-04-09	1999-10-04	Lilly Co Eli	Treatment of central nervous system disorders with selective estrogen receptor modulators.
US6025373A (en) *	1997-04-22	2000-02-15	Eli Lilly And Company	Methods for reducing fibrinogen
AU7470098A (en)	1997-04-30	1998-11-24	Eli Lilly And Company	Antithrombotic agents
JP2002513415A (ja)	1997-04-30	2002-05-08	イーライ・リリー・アンド・カンパニー	抗血栓剤
DE69824410T2 (de)	1997-04-30	2005-06-02	Eli Lilly And Co., Indianapolis	Antithrombosemittel
JP2002514217A (ja)	1997-04-30	2002-05-14	イーライ・リリー・アンド・カンパニー	抗血栓物質
US6103740A (en) *	1997-08-21	2000-08-15	Eli Lilly And Company	Methods for lowering platelet counts
US6187777B1 (en)	1998-02-06	2001-02-13	Amgen Inc.	Compounds and methods which modulate feeding behavior and related diseases
TR200002855T2 (tr) *	1998-04-08	2000-12-21	Eli Lilly And Company	Raloksifenin solunum yolu ile veya burundan uygulanması.
FR2777784B1 (fr) *	1998-04-27	2004-03-19	Arepa	Composition pharmaceutique a base d'estrogene et de progesterone
US6284756B1 (en)	1998-04-30	2001-09-04	Eli Lilly And Company	Antithrombotic agents
WO1999065489A1 (en)	1998-06-16	1999-12-23	Eli Lilly And Company	Methods for increasing levels of acetylcholine
US6288108B1 (en)	1998-06-16	2001-09-11	Eli Lilly And Company	Methods for increasing levels of acetylcholine
US6353003B1 (en)	1998-06-17	2002-03-05	Eli Lilly And Company	Method for reducing levels of homocysteine and C-reactive protein
EP0997460B1 (de) *	1998-10-28	2002-12-11	Eli Lilly And Company	Benzothiophenderivate als antithrombotische Mitteln und Zwischenprodukte
IL146284A0 (en)	1999-05-04	2002-07-25	Strakan Ltd	Androgen glycosides and pharmaceutical compositions containing the same
US6613083B2 (en)	2001-05-02	2003-09-02	Eckhard Alt	Stent device and method
JP3887588B2 (ja) *	2002-08-30	2007-02-28	株式会社リガク	Ｘ線回折による応力測定法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4133814A (en) *	1975-10-28	1979-01-09	Eli Lilly And Company	2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) *	1981-04-03	1983-04-19	Eli Lilly And Company	Synthesis of acylated benzothiophenes
US4418068A (en) *	1981-04-03	1983-11-29	Eli Lilly And Company	Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) *	1987-03-24	1991-12-24	University Of Pennsylvania	Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) *	1988-10-31	1995-03-07	Endorecherche Inc.	Anti-estrogenic compounds and compositions
JP3157882B2 (ja) *	1991-11-15	2001-04-16	帝国臓器製薬株式会社	新規なベンゾチオフエン誘導体

1993
- 1993-12-21 US US08/171,394 patent/US5441965A/en not_active Expired - Fee Related
1994
- 1994-12-19 NZ NZ270185A patent/NZ270185A/en unknown
- 1994-12-19 ZA ZA9410084A patent/ZA9410084B/xx unknown
- 1994-12-19 UA UA94129200A patent/UA29446C2/uk unknown
- 1994-12-19 CA CA002138493A patent/CA2138493A1/en not_active Abandoned
- 1994-12-19 IL IL11204894A patent/IL112048A/en not_active IP Right Cessation
- 1994-12-19 JP JP6314564A patent/JPH07223947A/ja active Pending
- 1994-12-19 TW TW083111851A patent/TW321601B/zh active
- 1994-12-19 KR KR1019940034935A patent/KR950016744A/ko not_active Ceased
- 1994-12-19 RU RU94045846/14A patent/RU94045846A/ru unknown
- 1994-12-19 ES ES94309472T patent/ES2102154T3/es not_active Expired - Lifetime
- 1994-12-19 EP EP94309472A patent/EP0664126B1/de not_active Expired - Lifetime
- 1994-12-19 CN CN94119741A patent/CN1078070C/zh not_active Expired - Fee Related
- 1994-12-19 DE DE69402173T patent/DE69402173T2/de not_active Expired - Fee Related
- 1994-12-19 DK DK94309472.2T patent/DK0664126T3/da active
- 1994-12-19 HU HU9403675A patent/HU224915B1/hu not_active IP Right Cessation
- 1994-12-19 NO NO19944932A patent/NO313081B1/no unknown
- 1994-12-19 AU AU81558/94A patent/AU693822B2/en not_active Ceased
- 1994-12-19 CZ CZ19943226A patent/CZ287725B6/cs not_active IP Right Cessation
- 1994-12-19 AT AT94309472T patent/ATE150308T1/de not_active IP Right Cessation
1995
- 1995-04-14 US US08/422,288 patent/US5508292A/en not_active Expired - Fee Related
- 1995-04-14 US US08/422,730 patent/US5688813A/en not_active Expired - Fee Related
1997
- 1997-05-23 GR GR970401187T patent/GR3023537T3/el unknown

Also Published As

Publication number	Publication date
US5441965A (en)	1995-08-15
US5688813A (en)	1997-11-18
CA2138493A1 (en)	1995-06-22
NO313081B1 (no)	2002-08-12
AU8155894A (en)	1995-06-29
EP0664126A1 (de)	1995-07-26
TW321601B (de)	1997-12-01
CZ322694A3 (en)	1995-09-13
KR950016744A (ko)	1995-07-20
EP0664126B1 (de)	1997-03-19
AU693822B2 (en)	1998-07-09
DE69402173D1 (de)	1997-04-24
RU94045846A (ru)	1996-10-20
GR3023537T3 (en)	1997-08-29
UA29446C2 (uk)	2000-11-15
HUT71344A (en)	1995-11-28
HU224915B1 (en)	2006-04-28
ES2102154T3 (es)	1997-07-16
NZ270185A (en)	1997-07-27
NO944932D0 (no)	1994-12-19
IL112048A (en)	1999-03-12
US5508292A (en)	1996-04-16
CN1107704A (zh)	1995-09-06
DK0664126T3 (da)	1997-09-01
CN1078070C (zh)	2002-01-23
HU9403675D0 (en)	1995-02-28
ZA9410084B (en)	1996-06-19
NO944932L (no)	1995-06-22
JPH07223947A (ja)	1995-08-22
DE69402173T2 (de)	1997-07-17
IL112048A0 (en)	1995-03-15
CZ287725B6 (en)	2001-01-17

Legal Events

Date	Code	Title	Description
1997-09-15	UEP	Publication of translation of european patent specification
2007-09-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE150308T1 (de)	1997-04-15	Hemmung von thrombin
DE69427800D1 (de)	2001-08-30	Methode zur Hemmung der Endometriose
DE69402165D1 (de)	1997-04-24	Hemmung von Seborrhoe und Akne
NO943878L (no)	1995-04-18	Hemming av uterinfibrose
NO943875D0 (no)	1994-10-13	Hemming av angiogenese og angiogene sykdommer
DE69412049D1 (de)	1998-09-03	Hemmung von dysfunctionalen Uterusblutungen
NO943873L (no)	1995-04-18	Hemming av bruskdegradering
DE69430940D1 (de)	2002-08-14	Methode zur Behandlung von resistenten Neoplasmen
DE69427807D1 (de)	2001-08-30	Hemmung von Hirsutismus und Alopecia bei Frauen